JP2016512194A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512194A5
JP2016512194A5 JP2015561540A JP2015561540A JP2016512194A5 JP 2016512194 A5 JP2016512194 A5 JP 2016512194A5 JP 2015561540 A JP2015561540 A JP 2015561540A JP 2015561540 A JP2015561540 A JP 2015561540A JP 2016512194 A5 JP2016512194 A5 JP 2016512194A5
Authority
JP
Japan
Prior art keywords
amino
bromophenyl
optionally substituted
carbamoyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015561540A
Other languages
English (en)
Japanese (ja)
Other versions
JP6196328B2 (ja
JP2016512194A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/020273 external-priority patent/WO2014138046A1/en
Publication of JP2016512194A publication Critical patent/JP2016512194A/ja
Publication of JP2016512194A5 publication Critical patent/JP2016512194A5/ja
Application granted granted Critical
Publication of JP6196328B2 publication Critical patent/JP6196328B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015561540A 2013-03-06 2014-03-04 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 Expired - Fee Related JP6196328B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361773778P 2013-03-06 2013-03-06
US61/773,778 2013-03-06
PCT/US2014/020273 WO2014138046A1 (en) 2013-03-06 2014-03-04 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017157337A Division JP6496788B2 (ja) 2013-03-06 2017-08-17 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用
JP2017157336A Division JP6496787B2 (ja) 2013-03-06 2017-08-17 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用

Publications (3)

Publication Number Publication Date
JP2016512194A JP2016512194A (ja) 2016-04-25
JP2016512194A5 true JP2016512194A5 (enExample) 2017-04-13
JP6196328B2 JP6196328B2 (ja) 2017-09-13

Family

ID=50389505

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015561540A Expired - Fee Related JP6196328B2 (ja) 2013-03-06 2014-03-04 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用
JP2017157336A Expired - Fee Related JP6496787B2 (ja) 2013-03-06 2017-08-17 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用
JP2017157337A Expired - Fee Related JP6496788B2 (ja) 2013-03-06 2017-08-17 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用
JP2019043933A Expired - Fee Related JP6672499B2 (ja) 2013-03-06 2019-03-11 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017157336A Expired - Fee Related JP6496787B2 (ja) 2013-03-06 2017-08-17 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用
JP2017157337A Expired - Fee Related JP6496788B2 (ja) 2013-03-06 2017-08-17 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用
JP2019043933A Expired - Fee Related JP6672499B2 (ja) 2013-03-06 2019-03-11 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用

Country Status (13)

Country Link
US (5) US20140256685A1 (enExample)
EP (1) EP2964214A1 (enExample)
JP (4) JP6196328B2 (enExample)
KR (2) KR20210024691A (enExample)
CN (2) CN105007908B (enExample)
AR (1) AR095035A1 (enExample)
AU (3) AU2014226001B2 (enExample)
BR (2) BR112015021392B1 (enExample)
CA (3) CA2899804A1 (enExample)
HK (2) HK1219661A1 (enExample)
RU (1) RU2696487C2 (enExample)
TW (1) TW201446241A (enExample)
WO (1) WO2014138046A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2770989T (pt) * 2011-10-26 2018-12-04 Allergan Inc Derivados de amida de aminoácidos substituídos por n-ureia como moduladores de recetor tipo-1 do recetor de péptidos formil (fprl-1)
WO2013158597A1 (en) * 2012-04-16 2013-10-24 Allergan, Inc. (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
WO2013171687A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CA2899804A1 (en) * 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
AU2014290618B2 (en) * 2013-07-16 2018-04-05 Allergan, Inc. Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
ES2639798T3 (es) 2013-07-18 2017-10-30 Idorsia Pharmaceuticals Ltd Derivados de espiro[2.4]heptano con puente sustituidos con piperazina como agonistas del receptor ALX
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
US9920013B2 (en) 2014-01-29 2018-03-20 Allergan, Inc. 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
US10301269B2 (en) 2014-05-21 2019-05-28 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
KR102772801B1 (ko) * 2015-12-10 2025-02-24 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
WO2017172761A1 (en) * 2016-03-28 2017-10-05 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
CA3020316A1 (en) * 2016-04-12 2017-10-19 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
CA3130536A1 (en) * 2016-10-06 2018-04-12 Daiichi Sankyo Company, Limited Urea derivative
GB2561540A (en) * 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
ES2799098B2 (es) * 2019-06-10 2021-12-10 Univ Madrid Carlos Iii Aptameros agonistas del receptor fpr2 y usos de los mismos

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
JPS63232846A (ja) 1987-03-20 1988-09-28 Haruo Ogura 新規な固定相担体
AU6909300A (en) * 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
EP1537075B1 (en) * 2002-09-05 2009-07-01 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
KR20090121832A (ko) * 2008-05-23 2009-11-26 인제대학교 산학협력단 2-(2-히드록시벤조일)히드라진카르복시아미드 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를유효 성분으로 함유하는 선택적 면역 억제용 약학적 조성물
EP2963012B1 (en) * 2008-11-11 2018-01-10 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
WO2010104306A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2011073918A2 (en) * 2009-12-16 2011-06-23 Actelion Pharmaceuticals Ltd Peptides as modulators of fprl1 and/or fprl2
CA2803920A1 (en) * 2010-06-24 2011-12-29 Richard Beard Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CA2819457A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
WO2012109544A1 (en) 2011-02-11 2012-08-16 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US20120329873A1 (en) 2011-06-17 2012-12-27 Li yong-xin D-serine for the treatment of visual system disorders
CA2841983A1 (en) * 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
PT2770989T (pt) * 2011-10-26 2018-12-04 Allergan Inc Derivados de amida de aminoácidos substituídos por n-ureia como moduladores de recetor tipo-1 do recetor de péptidos formil (fprl-1)
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
CA2864893A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
WO2013158597A1 (en) * 2012-04-16 2013-10-24 Allergan, Inc. (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
RU2663911C2 (ru) * 2013-03-06 2018-08-13 Аллерган, Инк. Применение агонистов формилпептидного рецептора 2 для лечения воспалительных заболеваний глаз
CA2899804A1 (en) * 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
AU2014290618B2 (en) * 2013-07-16 2018-04-05 Allergan, Inc. Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
US20150080466A1 (en) 2013-09-19 2015-03-19 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
AU2014352922B2 (en) 2013-11-21 2018-06-07 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
US10301269B2 (en) * 2014-05-21 2019-05-28 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators

Similar Documents

Publication Publication Date Title
RU2015134778A (ru) Применение агонистов формилпептидного рецептора 2 для лечения дерматологических заболеваний
RU2015136774A (ru) Применение агонистов формилпептидного рецептора 2 для лечения воспалительных заболеваний глаз
JP2016512193A5 (enExample)
RU2424233C2 (ru) Производные бензимидазола, методы их получения, применение их в качестве агонистов фарнезоид-х-рецептора (fxr) и содержащие их фармацевтические препараты
KR101363278B1 (ko) 이미다졸계 ｌｘｒ 변조제
RU2014120013A (ru) Амидные производные n-карбамид-замещенных аминокислот как модуляторы формилпептидного рецептора-1 (fprl-1)
RU2014122753A (ru) Производные 2,5-диоксоимидазолидин-1-ил-3-фенилмочевины в качестве модуляторов формилпептидного рецептора 1 (fprl-1)
RU2012117885A (ru) 2,3,5-тризамещенные пирролы, фармацевтическая композиция и лекарственное средство (варианты) на их основе, способ получения соединений (варианты)
JP2013506637A5 (enExample)
KR20050025189A (ko) 화학 화합물
AU2009217518A1 (en) 2-aminoimidazole beta-secretase inhibitors for the treatment of Alzheimer's disease
RU2011107227A (ru) Бензоимидазольные производные и ингибиторы гликоген-синтаза-киназы-3 бета, содержащие такие производные
EA200970604A1 (ru) Новое промежуточное соединение и способ, используемый для получения {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
BG65858B1 (bg) 1,2-диарилбензимидазоли и фармацевтичното им използване
JP2006522820A5 (enExample)
HRP20170338T1 (hr) Fluorometil-supstituirani pirolkarboksamidi
JP2001039870A (ja) 片頭痛治療のための組み合わせ療法
AR068065A1 (es) Derivados de tetrahidroquinolinas, antagonistas de receptores de tsh, composiciones farmaceuticas que los contienen y usos de los mismos en enfermedades asociadas a desordenes tiroideos.
JP2010533185A5 (enExample)
JP2012528843A5 (enExample)
TH93934B (th) เกลือมาเอลเอต, ทอสิเลต, ฟิวมาเรต, และออกซาเลตของ5-(1(s)-อะมิโน-2-ไฮดรอกซีเอธิล)- -n-[(2,4-ไดฟลูออโร-เฟนิล)-เมธิล]-2-[8-เมธอกซี-2-(ไตรฟลูออโรเมธิล)-5-ควิโนลีน]-4-ออกซาโซลคาร์บอกซามีด และกระบวนการของการเตรียมเพื่อประสงค์อย่างนั้น